HC Wainwright & Co. Maintains Buy on Aquestive Therapeutics, Raises Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju maintains a 'Buy' rating on Aquestive Therapeutics (NASDAQ:AQST) and raises the price target from $5 to $6.
November 08, 2023 | 1:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aquestive Therapeutics' price target has been raised from $5 to $6 by HC Wainwright & Co. The firm maintains a 'Buy' rating on the stock.
The raised price target and maintained 'Buy' rating by HC Wainwright & Co. indicates a positive outlook for Aquestive Therapeutics. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100